Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker analyses from the ongoing Phase 3 study evaluating ...
Cellectis (the 'Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV- study presented today at ASGCT 2026 Annual Meeting along with initial ...
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology ...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat ...
Pro, Llama 2, and medical-domain-tuned variants like Med-PaLM 2 have demonstrated remarkable capabilities in answering ...
Life Sciences Revenue -- $1.6 million, decreasing 48.4%, with R2 segment revenue mainly impacted by declines in Glacial FX ...
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global ...
Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session today at Heart Failure 2026.
The resignation of Santa Fe’s Alternative Response Unit manager leaves the program with five employees as concerns grow over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results